OBSERVATION VS INTENSIVE CHEMOTHERAPY FOR INDOLENT LYMPHOMA

“这项研究是12年前设计的， 比较两种非常有效的 对以前未经治疗的患者采取不同的治疗方法 惰性淋巴瘤患者：观察或延迟治疗 （观察和等待）与初始强化联合化疗 使用ProMACE/MOPP灵活疗法达到完全缓解， 然后进行巩固性改良全结节照射。迄今 无病生存率或总体 生存率，尽管完全缓解率存在差异 两个随机化组之间，76%的患者 随机接受强化治疗，达到完全缓解 相比之下，在一段时间的治疗后，CR率为37%。 观察.平均随访时间为10年。继续 随访可显示对一部分患者的益处。研究 已经关闭了进一步的患者招募。更长时间的随访 有必要确定是否有一个生存的差异， 不同的治疗方法。随机分配至WW的患者 手臂将继续交叉，并按照方案进行治疗。 自上次报告以来，没有发生交叉。"

"This study was designed twelve years ago to compare the efficacy and the long-term survival of two very different therapeutic approaches towards previously untreated patients with indolent lymphoma: observation or delayed therapy (watch and wait) vs. initial intensive combination chemotherapy with ProMACE/MOPP flexitherapy to complete remission, followed by consolidative modified total nodal irradiation. To date there are no significant differences in disease-free survival or overall survival, although there are differences in complete response rates between the two randomized groups with 76% of patients randomized to intensive therapy achieving a complete response compared to a CR rate of 37% in those treated after a period of observation. The median follow-up time is ten years. Continued follow-up may show a benefit for a subset of patients. The study has been closed to further patient accrual. Longer follow-up is necessary to determine if there is a survival difference between the different treatment approaches. Patients randomized to the WW arm will continue to be crossed over and treated per protocol. There have been no crossovers since the last report."